Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Investor Relations
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Stern Investor Relations, Inc.
William Gramig
william.gramig@sternir.com
Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200 x4801
help@astfinancial.com
www.astfinancial.com